Staff and business scale
The company has more than 3,200 employees and about 4,000 employees worldwide. Mainly focusing on the research, development, production and sales of biosynthetic human insulin and its analogues, it is an important participant in the diabetes market in China.
Technology research and development and product line
Li Gan Pharmaceutical Co., Ltd. is the first company in China to master the industrial production technology of recombinant insulin analogues, and has a complete insulin research and development pipeline. At present, there are many kinds of recombinant insulin analogues, including long-acting insulin glargine (Chang Xiulin _), quick-acting insulin lispro (Su Xiulin _), refined protein zinc recombinant insulin lispro mixed injection (25R) (Su Xiulin _25), insulin aspart (Rui Xiulin _) and so on. The product line also covers pre-filled injection pens and reusable insulin injection pens to meet the needs of three insulin functional market segments: long-acting, quick-acting and medium-acting.
Market positioning and business development
Li Gan Pharmaceutical is in a leading position in the diabetes market in China, and actively explores overseas markets. The company is committed to breaking the foreign monopoly on the insulin market and making domestic human insulin and its analogues occupy a dominant position in the China market.
The business has expanded to more than 20 countries and regions such as Europe and South America.
Corporate culture and vision
Li Gan Pharmaceutical adheres to scientific and ultimate corporate culture, and is committed to providing high-quality products and services for diabetics all over the world. The company's mission is to break the foreign monopoly of the insulin market, invest all resources, and constantly improve the level of clinicians' medication and the living standards of diabetic patients.
social responsibility
During the COVID-19 epidemic, Li Gan Pharmaceutical actively donated 1 10,000 yuan to the Beijing Red Cross for the prevention and control of new pneumonia. The company also urgently purchased and deployed nearly 580,000 yuan of emergency epidemic prevention medical materials at home and abroad, and rushed to 36/kloc-0 hospitals in Beijing, Tianjin and Hebei, providing necessary material support for epidemic prevention and control.
Precision poverty alleviation and disability assistance: In recent years, Li Gan Pharmaceutical has continuously increased its investment in public welfare projects such as precision poverty alleviation and disability assistance.
The company has donated millions of yuan to poor areas to help poor households get rid of poverty and become rich. Through cooperation with Dakang Service Center for the Disabled in Tongzhou District, Li Gan Pharmaceutical has established labor relations with more than 70 severely disabled people, which has promoted high-quality employment for the disabled.
Product R&D and innovation: Li Gan Pharmaceutical continues to invest heavily in product R&D and innovation, aiming at providing better treatment for diabetic patients. The company's investment in R&D accounts for a large proportion of sales revenue. For example, in 2020, R&D investment will reach 503 million yuan, accounting for 65,438+04.97% of sales revenue.